ABNOM
☆ AI Dermatology — Free Service
Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
relevance score : -100.0%
ReferencesDe Q‑switched Nd:YAG‑laser is bekend om effektyf nevus of Ota en ferlykbere betingst te behanneljen. Wy hawwe in stúdzje útfierd om te sjen hoe goed in high‑fluence 1064 nm Q‑switched Nd:YAG‑laser wurket op Mongoalske flekken yn ûngewoane gebieten, sûnder dat de hûd ljochter wurdt. Wy studearren 61 pasjinten mei dizze flekken, ûnderwiisd yn totaal 70 lesions. De helte fan de lesions waard behannele mei de laser, wylst de oare net behannele waarden foar fergeliking. Wy evaluearren de resultaten mei in skaal en mei in apparaat neamd Mexameter® om melaninenivo's te mjitten. Pasjinten waarden folge foar in gemiddelde fan 14 moannen yn 'e behannelingsgroep en 18 moannen yn' e observaasjegroep. Oan 'e ein fan de stúdzje fûnen wy signifikante ferskillen yn skaalpunten en melaninenivo's tusken de behannele en net‑behannelde groepen, mei de laser‑behannelde groep dy't bettere resultaten liet sjen. De high‑fluence Q‑switched Nd:YAG‑laser, sûnder hûdferljochting te feroarsaakjen, bewiist effektyf en feilich te wêzen foar it behanneljen fan dizze ûngewoane Mongoalske flekken.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Wy studearren de effektiviteit en feiligens fan it brûken fan in spesifike laserbehanneling foar ABNOM, en seagen op hokker faktoaren dit beynfloedzje kinne hoe goed it wurket. Wy seagen nei 110 pasjinten dy't ABNOM hiene en tusken twa en njoggen laserbehannelingen krigen. Wy fûnen dat de behanneling better wurke hoe langer it dien waard, mar net sa goed by âldere pasjinten. It wurke ek better yn pasjinten mei lichtere hûd (type III) en lytsere troffen gebieten (minder dan 10 cm²). Melasma, tegearre mei ABNOM, makke de behanneling minder effektyf. De kleur of it oantal troffen gebieten makket gjin ferskil. Lykwols krigen 10 % fan de pasjinten donkere plekken nei behanneling. Bettere resultaten bleaune by meardere behannelingen. Aldere pasjinten mei dûnkere hûd en donkere flekken hawwe mear kâns om nei behanneling donkere plekken te ûntwikkeljen. Foar pasjinten mei ABNOM en melasma is it better om in laser mei legere enerzjy te brûken om foarkommen dat it melasma fersterkt wurdt.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Behanneling
Whitening‑aginten helpe selden. Oars as melasma kin ABNOM ferbettere wurde mei laserbehanneling en kin fuortsmiten wurde sûnder weromkomst. Laserbehanneling kin 10 oant 20 kear útfierd wurde om ABNOM te behanneljen.
#QS1064 laser